Invasive Bladder Transitional Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Invasive Bladder Transitional Cell Carcinoma

MalaCards integrated aliases for Invasive Bladder Transitional Cell Carcinoma:

Name: Invasive Bladder Transitional Cell Carcinoma ¹² ¹⁵

Infiltrating Bladder Urothelial Carcinoma ⁷³

Invasive Bladder Urothelial Carcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:6477

NCIt ⁵⁰ C27885

UMLS ⁷³ C1334281

Sources

Summaries for Invasive Bladder Transitional Cell Carcinoma

MalaCards based summary : Invasive Bladder Transitional Cell Carcinoma, also known as infiltrating bladder urothelial carcinoma, is related to non-invasive bladder urothelial carcinoma and transitional cell carcinoma, and has symptoms including dysuria An important gene associated with Invasive Bladder Transitional Cell Carcinoma is NOTCH1 (Notch 1), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Cisplatin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and tongue, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Invasive Bladder Transitional Cell Carcinoma

Diseases related to Invasive Bladder Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)

#	Related Disease	Score	Top Affiliating Genes
1	non-invasive bladder urothelial carcinoma	12.4
2	transitional cell carcinoma	10.4
3	bladder urothelial carcinoma	10.3
4	splenic diffuse red pulp small b-cell lymphoma	10.1	NOTCH1 TP53
5	spinal cord astrocytoma	10.1	NOTCH1 TP53
6	richter's syndrome	10.1	NOTCH1 TP53
7	supratentorial cancer	10.1	NOTCH1 TP53
8	cerebrum cancer	10.1	NOTCH1 TP53
9	actinic cheilitis	10.1	CDKN1A TP53
10	bladder transitional cell papilloma	10.1	CDKN1A TP53
11	atypical follicular adenoma	10.1	CDKN1A TP53
12	lip cancer	10.1	CDKN1A TP53
13	suppressor of tumorigenicity 3	10.1	CDKN1A TP53
14	malignant mesenchymoma	10.0	CDKN1A TP53
15	keratoacanthoma	10.0	CDKN1A TP53
16	retinal cancer	10.0	CDKN1A TP53
17	cervical adenocarcinoma	10.0	CDKN1A TP53
18	ocular cancer	10.0	CDKN1A TP53
19	prostate cancer	10.0
20	skin melanoma	10.0	CDKN1A TP53
21	anaplastic thyroid cancer	10.0	CDKN1A TP53
22	nervous system cancer	10.0	CDKN1A TP53
23	acute lymphocytic leukemia	10.0	NOTCH1 TP53
24	non-invasive bladder papillary urothelial neoplasm	10.0	TP53 UPK3A
25	li-fraumeni syndrome	10.0	CDKN1A TP53
26	vulvar disease	10.0	TP53 UPK3A
27	vulva cancer	9.9	TP53 UPK3A
28	tongue squamous cell carcinoma	9.9	NOTCH1 TP53
29	tongue cancer	9.9	CDKN1A NOTCH1 TP53
30	large intestine cancer	9.9	CDKN1A NOTCH1 TP53
31	brain cancer	9.9	CDKN1A NOTCH1 TP53
32	bladder disease	9.9	TP53 UPK3A
33	cervical cancer	9.9	CDKN1A NOTCH1 TP53
34	suppression of tumorigenicity 12	9.7	TP53 UPK3A
35	bladder cancer	9.7	CDKN1A TP53 UPK3A

Graphical network of the top 20 diseases related to Invasive Bladder Transitional Cell Carcinoma:

Sources

Symptoms & Phenotypes for Invasive Bladder Transitional Cell Carcinoma

UMLS symptoms related to Invasive Bladder Transitional Cell Carcinoma:

dysuria

GenomeRNAi Phenotypes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 17)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-108	9.62	CDKN1A
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	9.62	TP53
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.62	TP53
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-132	9.62	TP53
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	9.62	TP53
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.62	HOXA13
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-178	9.62	HOXA13
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	9.62	HOXA13 TP53
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.62	TP53
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	9.62	HOXA13
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	9.62	HOXA13
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	9.62	CDKN1A
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-35	9.62	TP53
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-39	9.62	CDKN1A HOXA13 TP53
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	9.62	CDKN1A
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-76	9.62	CDKN1A
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-88	9.62	CDKN1A

MGI Mouse Phenotypes related to Invasive Bladder Transitional Cell Carcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.26	CDKN1A HOXA13 NOTCH1 TP53
2	renal/urinary system	MP:0005367	9.02	CDKN1A HOXA13 NOTCH1 TP53 UPK3A

Sources

Drugs & Therapeutics for Invasive Bladder Transitional Cell Carcinoma

Drugs for Invasive Bladder Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Cisplatin

Approved

Phase 1, Phase 2,Phase 2,Not Applicable

15663-27-1

2767 441203 84093

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

Carboquone

CDDP

CHEBI:35852

CID441203

Cis Pt II

cis-[PtCl2(NH3)2]

cis-DDP

Cis-DDP

Cis-Diaminedichloroplatinum

cis-diamminedichloridoplatinum(II)

cis-Diamminedichloroplatinum

Cis-Diamminedichloroplatinum

cis-diamminedichloroplatinum(II)

cis-Dichlorodiammineplatinum(II)

Cismaplat

Cisplatine

cisplatino

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

CPD0-1392

CPDC

CPDD

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

nchembio773-comp1

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

trans-DDP

Trans-DDP

Trans-Diaminedichloroplatinum

trans-diamminedichloridoplatinum(II)

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

2

Methotrexate

Approved

Phase 1, Phase 2

59-05-2, 1959-05-2

126941

Synonyms:

4-amino-10-Methylfolate

4-amino-10-methylfolic acid

4-amino-10-Methylfolic acid

4-amino-N(10)-Methylpteroylglutamate

4-amino-N(10)-methylpteroylglutamic acid

4-amino-N(10)-Methylpteroylglutamic acid

Abitrexate

Amethopterin

Amethopterine

Antifolan

Arbitrexate

Dicesium salt methotrexate

Emtexate

Emtexic acid

Folex

HDMTX

Hydrate, methotrexate

L-Amethopterin

Ledertrexate

Ledertrexic acid

Metatrexan

Methopterin

Methotextrate

Methotrate

Methotrexat

Méthotrexate

Methotrexate hydrate

Methotrexate sodium

Methotrexate Sodium

Methotrexate, (D)-isomer

Methotrexate, (DL)-isomer

Methotrexate, dicesium salt

Methotrexate, disodium salt

Methotrexate, sodium salt

Methotrexatum

Methotrexic acid

Methylaminopterin

Methylaminopterinum

Metotrexato

Mexate

MTX

N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamate

N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid

N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid

N-Bismethylpteroylglutamic acid

N-Bismethylpteroylglutamic Acid

Rheumatrex

Sodium, methotrexate

Trexall

3

Vinblastine

Approved

Phase 1, Phase 2

865-21-4

241903 13342

Synonyms:

(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE

(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE

(2xi,3beta,4'beta,19xi)-vincaleukoblastine

(2α,2'β,3β,4α,5β)-vincaleukoblastine

(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate

143-67-9

1z2b

29060-LE

865-21-4

AC1L21JC

AC1L68D2

AC1MXZJ2

AC-20335

BIDD:PXR0201

Bio-0111

BRD-K01188359-065-02-5

BSPBio_001228

BSPBio_003594

C07201

C46H58N4O9

CCRIS 9002

Cell pharm brand OF vinblastine sulfate

Cellblastin

CHEBI:171516

CHEBI:27375

CHEMBL159

CHEMBL607706

CID13342

CID241903

CID3823887

CID6710780

D08675

DB00570

EG labo brand OF vinblastine sulfate

EINECS 212-734-0

Faulding brand OF vinblastine sulfate

Gastrozepin brand OF vinblastine sulfate

Gry brand OF vinblastine sulfate

Hexal brand OF vinblastine sulfate

HMS2090K05

HSDB 3263

KBio3_003033

Lemblastine

Lemery brand OF vinblastine sulfate

Lilly brand OF vinblastine sulfate

LS-1859

LS-187263

MolPort-002-518-262

MolPort-005-910-359

NCGC00022585-04

NCGC00181127-01

NChemBio.2007.10-comp22

nchembio873-comp22

NCI60_004200

NCI-C04842

NDC 0002-1452-01

Neuro_000020

Nincaluicolflastine

NSC 47842

Rozevin

SPBio_000680

Spectrum2_000890

Spectrum3_001994

STOCK1N-38480

Sulfate, vinblastine

UNII-5V9KLZ54CY

Velban

Velbe

Vinblastin

Vinblastin hexal

Vinblastina

Vinblastina (TN)

Vinblastina [Dcit]

Vinblastina [DCIT]

Vinblastina lilly

vinblastine

Vinblastine

Vinblastine (INN)

Vinblastine [INN:BAN]

Vinblastine sulfate

Vinblastine Sulfate

Vinblastinsulfat-gry

Vinblastinum

Vinblastinum [INN-Latin]

Vincaleucoblastin

Vincaleucoblastine

Vincaleukoblastine

Vincoblastine

VLB

VR-8

4

Doxorubicin

Approved, Investigational

Phase 1, Phase 2

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-hydroxydaunomycin

14-Hydroxydaunomycin

14-hydroxydaunorubicine

14-Hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

adiblastine (hydrochloride salt)

ADM

ADR

adr iablatina (hydrochloride salt)

Adriablastin

Adriablastine

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin semiquinone

Adriamycin Semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (hydrochloride salt)

Adriblastina (TN)

Adriblastine

adriblatina (hydrochloride salt)

Adrimedac

Aerosolized Doxorubicin

Baxter brand OF doxorubicin hydrochloride

Bedford brand OF doxorubicin hydrochloride

BPBio1_000502

BRD-K92093830-003-04-3

Bristol-myers squibb brand OF doxorubicin hydrochloride

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

Caelyx

CCRIS 739

Cell pharm brand OF doxorubicin hydrochloride

CHEBI:28748

CHEMBL179

CID31703

Columbia brand OF doxorubicin hydrochloride

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

Doxil

Doxo

doxo Cell

doxo-Cell

Doxolem

doxorubicin

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin HCl

Doxorubicin hexal

Doxorubicin hydrochloride

Doxorubicin Hydrochloride

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin NC

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicina ferrer farm

Doxorubicina funk

Doxorubicina tedec

Doxorubicine

Doxorubicine [INN-French]

Doxorubicine baxter

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicinum

Doxorubicinum [INN-Latin]

Doxotec

DOX-SL

EINECS 245-495-6

Elan brand OF doxorubicin hydrochloride

Farmablastina (hydrochloride salt)

Farmiblastina

Ferrer brand OF doxorubicin hydrochloride

FI 106

Hexal brand OF doxorubicin hydrochloride

HMS2089H06

HSDB 3070

Hydrochloride, doxorubicin

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

Kenfarma brand OF doxorubicin hydrochloride

Lemery brand OF doxorubicin hydrochloride

LMPK13050001

LS-1029

LS-165655

Medac brand OF doxorubicin hydrochloride

MLS000759533

Myocet

NChemBio.2007.10-comp13

nchembio809-comp5

NCI-C01514

NDC 38242-874

Neocorp brand OF doxorubicin hydrochloride

NIOSH/JT9100000

NSC 123127

Onkodox

Onkoworks brand OF doxorubicin hydrochloride

Pfizer brand OF doxorubicin hydrochloride

Prasfarma brand OF doxorubicin hydrochloride

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Ribodoxo

Ribosepharm brand OF doxorubicin hydrochloride

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

Tedec meiji brand OF doxorubicin hydrochloride

ThermoDox

TLC D-99

Triferric doxorubicin

UNII-80168379AG

Urokit doxo cell

Urokit doxo-cell

5

Gemcitabine

Approved

Phase 2,Not Applicable

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DFDC

2',2'-DiF-dC

2',2'-difluoro-2'-Deoxycytidine

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate

2'-Deoxy-2'-difluorocytidine

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFdC

DFDC

DFdCyd

Folfugem

Gamcitabine

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

gemcitabine

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer

Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Gemcitabine, (D-threo-pentafuranosyl)-isomer

Gemcitabinum

Gemcitabinum [INN-Latin]

GemLip

Gemtro

Gemzar

Gemzar (hydrochloride)

GEO

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY188011

LY-188011

NCGC00168784-01

NChemBio.2007.10-comp25

nchembio.573-comp7

nchembio.90-comp2

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

Zefei

ZINC18279854

6

Tremelimumab

Investigational

Phase 1, Phase 2

745013-59-6

7

Doxil

Approved June 1999

Phase 1, Phase 2

31703

8

Antibodies, Monoclonal

Phase 1, Phase 2

9

Immunoglobulins

Phase 1, Phase 2

10

Antibodies

Phase 1, Phase 2

11

Immunologic Factors

Phase 1, Phase 2,Phase 2,Not Applicable

12

Antimetabolites

Phase 2,Not Applicable

13

Antiviral Agents

Phase 2,Not Applicable

14

Antimetabolites, Antineoplastic

Phase 2,Not Applicable

15

Immunosuppressive Agents

Phase 2,Not Applicable

16

Anti-Infective Agents

Phase 2,Not Applicable

17

Nivolumab

Approved

Phase 1

946414-94-4

18

Altretamine

Approved

Phase 1

645-05-6

2123

Synonyms:

2,4, 6-Tris(dimethylamino)-1,3,5-triazine

2,4,6-Tris(dimethylami

2,4,6-tris(dimethylamino)-1,3,5-triazine

2,4,6-Tris(dimethylamino)-1,3,5-triazine

2,4,6-tris(dimethylamino)-s-triazine

2,4,6-Tris(dimethylamino)-s-triazine

2,4,6-Tris(dimethylamino)-S-triazine

2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine

549835_ALDRICH

645-05-6

A 8723

A0567/0026158

A8723_SIGMA

AB00052308

AC-12006

AC1L1CYX

AI3-50852

AKOS001729401

Altretamin

Altretamina

Altretamina [INN-Spanish]

altretamine

Altrétamine

Altretamine (USP/INN)

Altretamine [USAN:INN:BAN]

Altretamine bellon brand

Altretamine Bellon Brand

Altretamine chiesi brand

Altretamine Chiesi Brand

Altretamine wassermann brand

Altretamine Wassermann Brand

Altretaminum

Altretaminum [INN-Latin]

Bellon brand OF altretamine

Bellon Brand of Altretamine

BPBio1_001004

BRD-K67043667-001-04-1

BRN 0195058

BSPBio_000912

C9H18N6

CAS-654-05-6

CCRIS 5492

CHEBI:24564

CHEMBL1455

ChemDiv2_005185

Chiesi brand OF altretamine

Chiesi Brand of Altretamine

CID2123

CPD000058181

D006585

D02841

DB00488

DivK1c_000772

EINECS 211-428-4

ENT 50852

EU-0100083

FT-0083576

Hemel

Hexalen

Hexalen (TN)

Hexalen, Altretamine

Hexamethylmelamine

HEXAMETHYLMELAMINE

Hexastat

Hexinawas

HMM

HMS1383L15

HMS1570N14

HMS1922C05

HMS2090G17

HMS2092H16

HMS502G14

HSDB 7559

HTM

HXM

I06-0604

IDI1_000772

IDI1_003900

InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H

KB-913

KBio1_000772

KBio2_001788

KBio2_004356

KBio2_006924

KBio3_002042

KBioGR_001388

KBioSS_001788

Lopac0_000083

Lopac-A-8723

LS-1549

MGI pharma brand OF altretamine

MGI Pharma Brand of Altretamine

MLS000069621

MLS001076123

MolPort-002-111-210

N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine

N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine

NC 195

NCGC00015100-01

NCGC00015100-02

NCGC00015100-03

NCGC00015100-06

NCGC00015100-11

NCGC00021216-03

NCGC00021216-04

NCGC00021216-05

NCGC00021216-06

NCGC00021216-07

NCI60_000871

NCI-C50259

NINDS_000772

no)-s-triazine

NSC 13875

NSC13875

NSC-13875

Prestwick0_000946

Prestwick1_000946

Prestwick2_000946

Prestwick3_000946

Rhone Poulenc Rorer Brand of Altretamine

Rhône poulenc rorer brand OF altretamine

Rhone-Poulenc Rorer Brand of Altretamine

Rhône-poulenc rorer brand OF altretamine

S1278_Selleck

SAM002564241

SMR000058181

SPBio_000754

SPBio_003071

Spectrum_001308

SPECTRUM1503065

Spectrum2_000907

Spectrum3_000951

Spectrum4_001064

Spectrum5_001092

ST086739

STK749184

UNII-Q8BIH59O7H

Wassermann brand OF altretamine

Wassermann Brand of Altretamine

WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1

ZINC00000905

19

Immunoglobulin G

Phase 1

Interventional clinical trials:

(show all 13)

#	Name	Status	NCT ID	Phase	Drugs
1	NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma	Recruiting	NCT03549715	Phase 1, Phase 2	Durvalumab;Tremelimumab;MVAC Protocol
2	Bristol Bladder Trial	Recruiting	NCT01616875	Phase 2	Cabazitaxel + Cisplatin chemotherapy
3	A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer	Recruiting	NCT01495676	Phase 2
4	Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer	Recruiting	NCT03609216	Phase 2	Gemcitabine Hydrochloride;Cisplatin
5	Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer	Not yet recruiting	NCT03744793	Phase 2	Avelumab;Pemetrexed
6	Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer	Withdrawn	NCT03419130	Phase 2
7	Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery	Recruiting	NCT02812420	Phase 1
8	Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	Recruiting	NCT02496208	Phase 1	Cabozantinib S-malate
9	sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer	Recruiting	NCT02767921	Phase 1
10	Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma	Withdrawn	NCT03430687	Phase 1
11	Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer	Recruiting	NCT02688348	Not Applicable
12	Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors	Withdrawn	NCT03238664	Not Applicable
13	Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery	Withdrawn	NCT02944357	Not Applicable	Cisplatin;Gemcitabine Hydrochloride

Search NIH Clinical Center for Invasive Bladder Transitional Cell Carcinoma

Sources

Genetic Tests for Invasive Bladder Transitional Cell Carcinoma

Sources

Anatomical Context for Invasive Bladder Transitional Cell Carcinoma

MalaCards organs/tissues related to Invasive Bladder Transitional Cell Carcinoma:

⁴¹

Skin, Brain, Tongue, Spinal Cord, Prostate, Thyroid, B Cells

Sources

Publications for Invasive Bladder Transitional Cell Carcinoma

Articles related to Invasive Bladder Transitional Cell Carcinoma:

#	Title	Authors	Year
1	Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. ( 24196429 )		2013
2	Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma. ( 23479173 )		2013
3	Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. ( 23609182 )		2013
4	[Expression analysis of NOTCH1/HES1/PTEN signaling pathway in invasive bladder transitional cell carcinoma]. ( 22781569 )	Sima J....Zhang X.	2012
5	Proteomics research on muscle-invasive bladder transitional cell carcinoma. ( 21645413 )		2011
6	Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. ( 17222615 )		2007
7	Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. ( 17011058 )		2006
8	Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. ( 11696726 )	Tiguert R....Sarkar F.H.	2001

Sources

Genes for Invasive Bladder Transitional Cell Carcinoma

Genes related to Invasive Bladder Transitional Cell Carcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	NOTCH1	Notch 1	Protein Coding	20.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	TP53	Tumor Protein P53	Protein Coding	20.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	17.03	GeneCards inferred via : Publications (show sections)
4	HOXA13	Homeobox A13	Protein Coding	15.14	DISEASES inferred ¹⁵
5	UPK3A	Uroplakin 3A	Protein Coding	14.93	DISEASES inferred ¹⁵
6	TPBG	Trophoblast Glycoprotein	Protein Coding	14.93	DISEASES inferred ¹⁵

Sources

Variations for Invasive Bladder Transitional Cell Carcinoma

Sources

Expression for Invasive Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Invasive Bladder Transitional Cell Carcinoma.

Sources

Pathways for Invasive Bladder Transitional Cell Carcinoma

Pathways related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁷	12.48	CDKN1A NOTCH1 TP53
2	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.39	CDKN1A NOTCH1 TP53
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.38	CDKN1A NOTCH1 TP53
4	MicroRNAs in cancer ³⁷	12.02	CDKN1A NOTCH1 TP53
5	Small cell lung cancer ³⁷	11.57	CDKN1A TP53
6	Retinoblastoma (RB) in Cancer ¹	11.54	CDKN1A TP53
7	ATM Pathway ⁶⁴ Show member pathways ATM Signaling Pathway ¹	11.53	CDKN1A TP53
8	Glucocorticoid receptor regulatory network ¹	11.49	CDKN1A TP53
9	Primary Focal Segmental Glomerulosclerosis FSGS ¹	11.44	CDKN1A NOTCH1
10	Platinum drug resistance ³⁷	11.42	CDKN1A TP53
11	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.34	NOTCH1 TP53
12	Hepatitis C and Hepatocellular Carcinoma ¹	11.22	CDKN1A TP53
13	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.2	CDKN1A TP53
14	miRNAs involved in DNA damage response ¹	11.18	CDKN1A TP53
15	Integrated Cancer Pathway ¹	11.12	CDKN1A TP53
16	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.08	CDKN1A TP53
17	Signaling events mediated by HDAC Class III ¹	11	CDKN1A TP53
18	GADD45 Pathway ⁶⁴	10.83	CDKN1A TP53
19	Bladder cancer ³⁷ ¹	10.66	CDKN1A TP53 UPK3A
20	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.6	CDKN1A TP53
21	LncRNA-mediated mechanisms of therapeutic resistance ¹	10.23	CDKN1A TP53
22	Transcriptional activation of p53 responsive genes ⁶⁶ Show member pathways Transcriptional activation of cell cycle inhibitor p21 ⁶⁶	9.86	CDKN1A TP53

Sources

GO Terms for Invasive Bladder Transitional Cell Carcinoma

Cellular components related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endoplasmic reticulum	GO:0005783	8.92	NOTCH1 TP53 TPBG UPK3A

Biological processes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell proliferation	GO:0008285	9.63	CDKN1A NOTCH1 TP53
2	Ras protein signal transduction	GO:0007265	9.48	CDKN1A TP53
3	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.43	CDKN1A TP53
4	animal organ regeneration	GO:0031100	9.4	CDKN1A NOTCH1
5	cellular response to ionizing radiation	GO:0071479	9.37	CDKN1A TP53
6	intrinsic apoptotic signaling pathway	GO:0097193	9.32	CDKN1A TP53
7	positive regulation of reactive oxygen species metabolic process	GO:2000379	9.26	CDKN1A TP53
8	replicative senescence	GO:0090399	9.16	CDKN1A TP53
9	cell cycle arrest	GO:0007050	9.13	CDKN1A NOTCH1 TP53
10	signal transduction by p53 class mediator	GO:0072331	8.62	CDKN1A TP53

Sources

Sources for Invasive Bladder Transitional Cell Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia